Literature DB >> 25291152

Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Natalícia de Jesus Antunes1, Ricardo Carvalho Cavalli, Maria Paula Marques, Elaine Christine Dantas Moisés, Vera Lucia Lanchote.   

Abstract

AIM: To investigate the influence of gestational diabetes mellitus (GDM) on the kinetic disposition and transplacental and amniotic fluid distribution of metoprolol and its metabolites O-desmethylmetoproloic acid and α-hydroxymetoprolol stereoisomers in hypertensive parturients receiving a single dose of the racemic drug.
METHODS: The study was conducted on hypertensive parturients with well-controlled GDM (n = 11) and non-diabetic hypertensive parturients (n = 24), all receiving a single 100 mg oral dose of racemic metoprolol tartrate before delivery. Serial maternal blood samples (0-24 h) and umbilical blood and amniotic fluid samples were collected for the quantitation of metoprolol and its metabolite stereoisomers using LC-MS/MS or fluorescence detection.
RESULTS: The kinetic disposition of metoprolol and its metabolites was stereoselective in the diabetic and control groups. Well-controlled GDM prolonged tmax for both enantiomers of metoprolol (1.5 vs. 2.5 h R-(+)-MET; 1.5 vs. 2.75 h S-(-)-MET) and O-desmethylmetoproloic acid (2.0 vs. 3.5 h R-(+)-AOMD; 2.0 vs. 3.0 h S-(-)-OAMD), and for the four stereoisomers of α-hydroxymetoprolol (2.0 vs. 3.0 h for 1'S,2R-, 1'R,2R- and 1'R,2S-OHM; 2.0 vs. 3.5 h for 1'S,2S-OHM) and reduced the transplacental distribution of 1'S,2S-, 1'R,2R-, and 1'R,2S-OHM by approximately 20%.
CONCLUSIONS: The kinetic disposition of metoprolol was enantioselective, with plasma accumulation of the S-(-)-MET eutomer. Well-controlled GDM prolonged the tmax of metoprolol and O-desmethylmetoproloic acid enantiomers and the α-hydroxymetoprolol stereoisomers and reduced by about 20% the transplacental distribution of 1'S,2S-, 1'R,2R-, and 1'R,2S-OHM. Thus, well-controlled GDM did not change the activity of CYP2D6 and CYP3A involved in metoprolol metabolism.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  arterial hypertension; enantiomers; gestational diabetes mellitus; metoprolol; parturients; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25291152      PMCID: PMC4386945          DOI: 10.1111/bcp.12523

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  50 in total

1.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

2.  Antihypertensive treatment with the adrenergic beta-receptor blocker metoprolol during pregnancy.

Authors:  B Sandström
Journal:  Gynecol Invest       Date:  1978

3.  Increased oral clearance of metoprolol in pregnancy.

Authors:  S Högstedt; B Lindberg; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Determination of two metoprolol metabolites in human urine by high-performance liquid chromatography.

Authors:  J Godbillon; M Duval
Journal:  J Chromatogr       Date:  1984-07-13

5.  Stereoselective determination of metoprolol and its metabolite α-hydroxymetoprolol in plasma by LC-MS/MS: application to pharmacokinetics during pregnancy.

Authors:  Natalícia De Jesus Antunes; Ricardo Carvalho Cavalli; Maria Paula Marques; Vera Lucia Lanchote
Journal:  Chirality       Date:  2012-10-24       Impact factor: 2.437

6.  Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?

Authors:  Andrew Collett; Jolanta Tanianis-Hughes; Geoff Warhurst
Journal:  Biochem Pharmacol       Date:  2004-08-15       Impact factor: 5.858

7.  Disposition of the adrenergic blocker metoprolol in the late-pregnant woman, the amniotic fluid, the cord blood and the neonate.

Authors:  S Lindeberg; B Sandström; P Lundborg; C G Regårdh
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1984

8.  In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

Authors:  S V Otton; R U Brinn; L F Gram
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

9.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Authors:  M A Laurent-Kenesi; C Funck-Brentano; J M Poirier; D Decolin; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

Review 10.  Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress.

Authors:  Shinji Kawahito; Hiroshi Kitahata; Shuzo Oshita
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

View more
  3 in total

1.  A method to determine pharmacokinetic parameters based on andante constant-rate intravenous infusion.

Authors:  Rui-Hong Yu; Yong-Xiao Cao
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

2.  Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods.

Authors:  Huizi Ouyang; Jiayuan Shen; Xuhua Huang; Wenjuan Ma; Qi Jia; Guangzhe Yao; Zhidan Tang; Dandan Zhang; Mengjie Sun; John Teye Azietaku; Jia Hao; Xiumei Gao; Yanxu Chang; Jun He
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-23       Impact factor: 2.629

Review 3.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.